📌 Key Highlights & Quick Takeaways:
- LONDON: A major medical breakthrough has come for melanoma patients, where the world's first personalized cancer vaccine, when used with imm.
- According to the report, 1,137 patients were included in a large phase III clinical trial.
- The research used a personalized 'mRNA' vaccine with the well-known immunotherapy drug Truda, the results of which have given experts hope t.
LONDON: A major medical breakthrough has come for melanoma patients, where the world's first personalized cancer vaccine, when used with immunotherapy, reduced the risk of the cancer returning or dying by 42 percent.
According to the report, 1,137 patients were included in a large phase III clinical trial.
The research used a personalized 'mRNA' vaccine with the well-known immunotherapy drug Truda, the results of which have given experts hope that a vaccine tailored to a patient's own disease could play a major role in future cancer treatments.
According to the study, patients who received the combination of the vaccine and immunotherapy had a 42 percent lower risk of melanoma spreading to other parts of the body or death over two years, and a nearly 38 percent lower risk of the disease spreading, compared to patients who received immunotherapy alone.
Melanoma is a dangerous type of skin cancer and causes around 2,600 deaths in the UK each year. Among patients with the most severe form of the disease, the survival rate five years after diagnosis was also reduced to about one-third.
